Firefly Neuroscience, Inc. (AIFF) stock forecast & analysis
1.63
NasdaqCM · USD
Down: -0.38, -18.9%
1 analysis
- Open
- 1.76
- Previous close
- 2.01
- Day range
- 1.55 – 1.79
- 52-week range
- 0.6200 – 3.15
- Volume (shares)
- 3.12M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 15.69M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -3.88
- Market cap
- 25.58M
Market Scanner’s AI analysis of Firefly Neuroscience, Inc. (AIFF), updated September 2026: Firefly Neuroscience's Evoke Platform integration and ADHD treatment partnership highlighted amid strong revenue growth and technical bullishness.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Firefly Neuroscience, Inc. (AIFF) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Firefly Neuroscience's Evoke Platform integration and ADHD treatment partnership highlighted amid strong revenue growth and technical bullishness.
Recent analyses for Firefly Neuroscience (AIFF) covered significant advancements including the integration of its Evoke Platform with Radial's AI-native operating system and a partnership with NeuroSigma to expand access to a pediatric ADHD treatment. The company also reported a substantial increase in TMS center customer brain scan volumes and strong year-over-year quarterly revenue growth. However, ongoing losses were noted, with negative operating and return on equity margins.
AIFF news & sentiment
News headlines highlighted a positive trajectory for Firefly Neuroscience, emphasizing a significant partnership to broaden treatment access and the integration of its Evoke Platform with a new AI operating system. News also detailed a substantial surge in customer brain scan volumes, indicating growing adoption of the company's technology.
AIFF technical picture
AIFF's price action showed a strong uptrend, significantly outperforming its moving averages. Momentum indicators signaled extreme buying pressure and overbought conditions, with high readings on the Relative Strength Index and Money Flow Index.
Fundamentals
Firefly Neuroscience (AIFF) reported significant year-over-year quarterly revenue growth, though it continues to incur substantial operating and net losses. The company's trailing twelve months operating margin and return on equity remain negative, indicating ongoing profitability challenges despite gross profit generation.
Factors discussed — upside
- Year-over-year quarterly revenue growth of 71.9%
- Partnership with NeuroSigma for pediatric ADHD treatment
- Integration of Evoke Platform with Radial's AI-native operating system
- 291% increase in TMS center customer brain scan volumes
- Strong bullish technical indicators including price outperforming moving averages and high momentum readings
Factors discussed — risks
- TTM operating margin of -494.2%
- TTM Return on Equity of -68.1%
- Latest quarter operating loss of $1,974,000
- Latest quarter net loss of $1,984,000
- Revenue growth
- Partnerships and integrations
- Technical indicators
- Profitability challenges
Summary updated .
AIFF technical indicators
Common technical indicators for AIFF, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.14 | Price above |
| 10-day exponential moving average | 1.37 | Price above |
| Relative strength index (14-day) | 62.69 | Neutral |
| MACD line (12/26/9) | 0.1085 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.72 – 1.66 | Price inside the bands |
Analyses
Recent AIFF.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Firefly Neuroscience, Inc.?
- The bull case for Firefly Neuroscience centers on significant revenue growth, driven by a 71.9% year-over-year increase in quarterly revenue and a 291% surge in TMS center customer brain scan volumes. Strategic developments, including a partnership with NeuroSigma to expand pediatric ADHD treatment access and the integration of its Evoke Platform with Radial's AI-native operating system, are expected to further bolster its market position. Strong bullish technical indicators also signal positive momentum.
- What are the risks for Firefly Neuroscience, Inc.?
- The primary risks for Firefly Neuroscience stem from its ongoing financial losses, evidenced by a TTM operating margin of -494.2% and a TTM Return on Equity of -68.1%. The company reported an operating loss of $1,974,000 and a net loss of $1,984,000 in its latest reported quarter, indicating significant profitability challenges.
- Is Firefly Neuroscience, Inc. bullish or bearish?
- Recent AI analyses of Firefly Neuroscience, Inc. examined factors on both sides. Discussed upside: The bull case for Firefly Neuroscience centers on significant revenue growth, driven by a 71.9% year-over-year increase in quarterly revenue and a 291% surge in TMS center customer brain scan volumes. Strategic developments, including a partnership with NeuroSigma to expand pediatric ADHD treatment access and the integration of its Evoke Platform with Radial's AI-native operating system, are expected to further bolster its market position. Strong bullish technical indicators also signal positive momentum. Discussed risks: The primary risks for Firefly Neuroscience stem from its ongoing financial losses, evidenced by a TTM operating margin of -494.2% and a TTM Return on Equity of -68.1%. The company reported an operating loss of $1,974,000 and a net loss of $1,984,000 in its latest reported quarter, indicating significant profitability challenges. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Firefly Neuroscience, Inc.?
- News headlines highlighted a positive trajectory for Firefly Neuroscience, emphasizing a significant partnership to broaden treatment access and the integration of its Evoke Platform with a new AI operating system. News also detailed a substantial surge in customer brain scan volumes, indicating growing adoption of the company's technology.
- How does Market Scanner analyse Firefly Neuroscience, Inc.?
- Every analysis of Firefly Neuroscience, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh AIFF.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.